BRAF V600E associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma

Endocrine

Volumn 44, Issue 1, 2013, Pages 165-171

  Guerra, Anna ^a   Marotta, Vincenzo ^b   Deandrea, Maurilio ^c   Motta, Manuela ^c   Limone, Paolo Piero ^c   Caleo, Alessia ^d   Zeppa, Pio ^a   Esposito, Silvano ^a   Fulciniti, Franco ^e   Vitale, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

BRAFV600E; CK19; Gal 3; p27Kip1; Thyroid cancer

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOKERATIN 19; GALECTIN 3;

ARTICLE; BENIGN TUMOR; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYROID CARCINOMA;

AMINO ACID SUBSTITUTION; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GLUTAMIC ACID; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; VALINE;

EID: 84881161816     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9843-4     Document Type: Article

References (45)

1. H. Gharib, J.R. Goellner, Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann. Intern. Med. 118(4), 282-289 (1993)
2. J.M. Miller, J.I. Hamburger, S. Kini, Diagnosis of thyroid nodules. Use of fine-needle aspiration and needle biopsy. JAMA 241(5), 481-484 (1979)
3. G. Jayaram, Fine needle aspiration cytologic study of the solitary thyroid nodule. Profile of 308 cases with histologic correlation. Acta Cytol. 29(6), 967-973 (1985)
4. J.L. Wang, R.M. Gray, K.C. Haudek, R.J. Patterson, Nucleocytoplasmic lectins. Biochim. Biophys. Acta 1673(1-2), 75-93 (2004)
5. E. Saggiorato, S. Cappia, P. De Giuli, A. Mussa, G. Pancani, P. Caraci, A. Angeli, F. Orlandi, Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J. Clin. Endocrinol. Metab. 86(11), 5152-5158 (2001)
6. F. Orlandi, E. Saggiorato, G. Pivano, B. Puligheddu, A. Termine, S. Cappia, P. De Giuli, A. Angeli, Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 58(14), 3015-3020 (1998)
7. J. Bojunga, S. Zeuzem, Molecular detection of thyroid cancer: an update. Clin Endocrinol (Oxf) 61(5), 523-530 (2004)
8. M. Niedziela, J. Maceluch, E. Korman, Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J. Clin. Endocrinol. Metab. 87(9), 4411-4415 (2002)
9. T. Takano, A. Miyauchi, F. Matsuzuka, H. Yoshida, K. Kuma, N. Amino, Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Lett. 199(1), 69-73 (2003)
10. M. Pagano, S.W. Tam, A.M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P.R. Yew, G.F. Draetta, M. Rolfe, Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269(5224), 682-685 (1995)
11. M. Loda, B. Cukor, S.W. Tam, P. Lavin, M. Fiorentino, G.F. Draetta, J.M. Jessup, M. Pagano, Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3(2), 231-234 (1997)
12. C. Catzavelos, N. Bhattacharya, Y.C. Ung, J.A. Wilson, L. Roncari, C. Sandhu, P. Shaw, H. Yeger, I. Morava-Protzner, L. Kapusta, E. Franssen, K.I. Pritchard, J.M. Slingerland, Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3(2), 227-230 (1997)
13. M. Mori, K. Mimori, T. Shiraishi, S. Tanaka, H. Ueo, K. Sugimachi, T. Akiyoshi, p27 expression and gastric carcinoma. Nat. Med. 3(6), 593 (1997)
14. L.A. Erickson, L. Jin, P.C. Wollan, G.B. Thompson, J. van Heerden, R.V. Lloyd, Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod. Pathol. 11(2), 169-174 (1998)
15. M.B. Resnick, P. Schacter, Y. Finkelstein, Y. Kellner, O. Cohen, Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod. Pathol. 11(8), 735-739 (1998)
16. M.L. Khoo, N.J. Beasley, S. Ezzat, J.L. Freeman, S.L. Asa, Overexpression of cyclin D1 and under expression of p27 predict lymph node metastases in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 87(4), 1814-1818 (2002)
17. L.P. Zhong, S.F. Zhao, G.F. Chen, F.Y. Ping, Z.F. Xu, J.A. Hu, Increased levels of CK19 mRNA in oral squamous cell carcinoma tissue detected by relative quantification with real-time polymerase chain reaction. Arch. Oral Biol. 51(12), 1112-1119 (2006)
18. J. Rosai, Immunohistochemical markers of thyroid tumors: significance and diagnostic applications. Tumori 89(5), 517-519 (2003)
19. L.M. Brown, S.M. Helmke, S.W. Hunsucker, R.T. Netea-Maier, S.A. Chiang, D.E. Heinz, K.R. Shroyer, M.W. Duncan, B.R. Haugen, Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol. Carcinog. 45(8), 613-626 (2006)
20. C.C. Cheung, S. Ezzat, J.L. Freeman, I.B. Rosen, S.L. Asa, Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod. Pathol. 14(4), 338-342 (2001)
21. M. Xing, W.H. Westra, R.P. Tufano, Y. Cohen, E. Rosenbaum, K.J. Rhoden, K.A. Carson, V. Vasko, A. Larin, G. Tallini, S. Tolaney, E.H. Holt, P. Hui, C.B. Umbricht, S. Basaria, M. Ewertz, A.P. Tufaro, J.A. Califano, M.D. Ringel, M.A. Zeiger, D. Sidransky, P.W. Ladenson, BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90(12), 6373-6379 (2005)
22. E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov, J.A. Fagin, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63(7), 1454-1457 (2003)
23. A. Guerra, M.R. Sapio, V. Marotta, E. Campanile, M.I. Moretti, M. Deandrea, M. Motta, P.P. Limone, G. Fenzi, G. Rossi, M. Vitale, Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr. J. 58(1), 31-38 (2011)
24. V. Marotta, A. Guerra, M.R. Sapio, M. Vitale, RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur. J. Endocrinol. 165(4), 499-507 (2011). doi: 10.1530/EJE-11-0499
25. M.R. Sapio, A. Guerra, V. Marotta, E. Campanile, R. Formisano, M. Deandrea, M. Motta, P.P. Limone, G. Fenzi, G. Rossi, M. Vitale, High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J. Clin. Endocrinol. Metab. 96(6), E916-E919 (2011). doi: 10.1210/jc.2010-1599
26. V. Marotta, M.R. Sapio, A. Guerra, M. Vitale, BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma. Expert. Opin. Med. Diagn. 5(4), 277-290 (2011)
27. N. Kurtulmus, M. Duren, U. Ince, M. Cengiz Yakicier, O. Peker, O. Aydin, E. Altiok, S. Giray, H. Azizlerli, BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42(2), 404-410 (2012). doi: 10.1007/s12020-012-9651-x
28. A. Guerra, L. Fugazzola, V. Marotta, M. Cirillo, S. Rossi, V. Cirello, I. Forno, T. Moccia, A. Budillon, M. Vitale, A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J. Clin. Endocrinol. Metab. 97(7), 2333-2340 (2012). doi: 10.1210/jc.2011-3106
29. M.R. Sapio, A. Guerra, D. Posca, P.P. Limone, M. Deandrea, M. Motta, G. Troncone, A. Caleo, P. Vallefuoco, G. Rossi, G. Fenzi, M. Vitale, Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr. Relat. Cancer 14(4), 1089-1097 (2007)
30. J. Rosai, M.L. Carcangiu, R.A. De Lellis, Tumors of the thyroid gland, in Atlas of tumor pathology third series fascicle 5, ed. by J. Rosai, L.H. Sobin (Armed Forces Institute of Pathology, Washington, 1992), pp. 49-62
31. M.R. Sapio, D. Posca, G. Troncone, G. Pettinato, L. Palombini, G. Rossi, G. Fenzi, M. Vitale, Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur. J. Endocrinol. 154(2), 341-348 (2006)
32. A. Guerra, M.R. Sapio, V. Marotta, E. Campanile, S. Rossi, I. Forno, L. Fugazzola, A. Budillon, T. Moccia, G. Fenzi, M. Vitale, The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 97(2), 517-524 (2012). doi: 10.1210/jc.2011-0618
33. R.M. Melillo, M.D. Castellone, V. Guarino, V. De Falco, A.M. Cirafici, G. Salvatore, F. Caiazzo, F. Basolo, R. Giannini, M. Kruhoffer, T. Orntoft, A. Fusco, M. Santoro, The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115(4), 1068-1081 (2005)
34. S. Akahani, P. Nangia-Makker, H. Inohara, H.R. Kim, A. Raz, Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 57(23), 5272-5276 (1997)
35. S.F. Dagher, J.L. Wang, R.J. Patterson, Identification of galectin-3 as a factor in pre-mRNA splicing. Proc. Natl. Acad. Sci. USA. 92(4), 1213-1217 (1995)
36. L. Chiariotti, M.T. Berlingieri, P. De Rosa, C. Battaglia, N. Berger, C.B. Bruni, A. Fusco, Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene 7(12), 2507-2511 (1992)
37. M.F. Beesley, K.M. McLaren, Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 41(3), 236-243 (2002)
38. S.W. Blain, J. Massague, Breast cancer banishes p27 from nucleus. Nat. Med. 8(10), 1076-1078 (2002)
39. J. Slingerland, M. Pagano, Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183(1), 10-17 (2000)
40. J. Vlach, S. Hennecke, B. Amati, Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 16(17), 5334-5344 (1997)
41. D. Vitagliano, F. Carlomagno, M.L. Motti, G. Viglietto, Y.E. Nikiforov, M.N. Nikiforova, J.M. Hershman, A.J. Ryan, A. Fusco, R.M. Melillo, M. Santoro, Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res. 64(11), 3823-3829 (2004)
42. M.L. Motti, D. Califano, G. Troncone, C. De Marco, I. Migliaccio, E. Palmieri, L. Pezzullo, L. Palombini, A. Fusco, G. Viglietto, Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am. J. Pathol. 166(3), 737-749 (2005)
43. H.S. Jung, D.W. Kim, Y.S. Jo, H.K. Chung, J.H. Song, J.S. Park, K.C. Park, S.H. Park, J.H. Hwang, K.W. Jo, M. Shong, Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol. Endocrinol. 19(11), 2748-2759 (2005)
44. G. Crouzeix, J.J. Michels, E. Sevin, N. Aide, D. Vaur, S. Bardet, Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 97(9), 3046-3050 (2012). doi: 10.1210/jc.2012-1630
45. V. Marotta, V. Ramundo, L. Camera, M.D. Prete, R. Fonti, R. Esposito, G. Palmieri, M. Salvatore, M. Vitale, A. Colao, A. Faggiano, Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin. Endocrinol. (Oxf) (2012). doi: 10.1111/cen.12057